Long Read Sequencing Market By Application, By Technique (Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Synthetic Long Read Sequencing), By Product, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

The long read sequencing market was valued at $724.43 million in 2022 and is estimated to reach $5,163.41 million by 2032, exhibiting a CAGR of 21.7% from 2023 to 2032. Long read sequencing is a genomic technique that reads longer stretches of DNA compared to traditional methods. It employs innovative technologies like single-molecule sequencing to generate DNA sequences spanning thousands to millions of base pairs. Platforms such as Pacific Biosciences and Oxford Nanopore Technologies utilize techniques such as nanopore sequencing to achieve extended read lengths. Long read sequencing facilitates comprehensive analysis of complex genomic regions, repetitive sequences, and structural variations. Its applications include de novo genome assembly, resolving complex genomic structures, understanding genetic diseases, and exploring microbial diversity. Overall, long read sequencing revolutionizes genomic research by providing detailed and accurate genomic information.

The rise in the prevalence of genetic disorders and cancer is indeed a significant driver for the increased demand for long read sequencing technologies. Genetic disorders and cancer are inherently complex diseases influenced by multiple genetic factors, including mutations, structural variations, and genomic rearrangements. Long read sequencing offers the ability to comprehensively analyze the entire genome, enabling researchers and clinicians to identify rare and novel genetic variants associated with these diseases more accurately. For instance, the World Health Organization (WHO) estimated that approximately 400,000 children develop cancer every year worldwide, emphasizing the urgent need for advanced genomic technologies to better understand the genetic basis of cancer and develop targeted therapies. By providing insights into the underlying genetic mechanisms of disease, long read sequencing plays a crucial role in advancing precision medicine initiatives and improving clinical outcomes for patients with genetic disorders and cancer.

In addition, with the decreasing cost of sequencing and increasing awareness of the importance of genomics in various domains, there's a growing demand for comprehensive genomic insights. Long read sequencing provides a deeper understanding of genomic structure and function, allowing researchers to uncover complex genetic variations and better understand the genetic basis of diseases, traits, and evolutionary processes. Thus, the rise in genetic and cancer disorders and the wide application of long read sequencing in the disease diagnosis is potentially diving the market growth.

However, the lack of skilled professionals in the field of long read sequencing is expected to hinder market growth. Operating and interpreting data from long read sequencing platforms require specialized expertise in molecular biology, bioinformatics, and genomics. The shortage of adequately trained personnel may limit the adoption and utilization of long read sequencing technologies, delaying their implementation in research, clinical diagnostics, and industrial applications.

The long read sequencing market is segmented on the basis of application, technique, product, end user, and region. By application, it is bifurcated into research application and clinical application. By technique, the market is categorized into single-molecule real-time sequencing (SMRT), nanopore sequencing and synthetic long read sequencing. On the basis of product, it is segmented into instruments, consumables, and services. The instrument segment is further classified into system and software. By end user, it is segregated into academic and government research institutes, pharmaceutical and biotechnological companies, hospitals and clinics, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global long read sequencing market are Agilent Technologies, Inc. BaseClear BV, Cantata Bio, FG Technologies, Grandomics, MicrobesNG, Novogene co., ltd., Oxford Nanopore Technologies, Pacific Biosciences Inc., CD Genomics, Danaher Corporation, BGI Genomics, St Vincent's Hospital Australia, Takara Holdings Inc., Thermo Fisher Scientific, Inc., Element Biosciences, and Illumina, Inc. Key players operating in the market have adopted product launch, acquisition, partnership and collaboration as their key strategy to expand their product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the long read sequencing market analysis from 2022 to 2032 to identify the prevailing long read sequencing market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the long read sequencing market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global long read sequencing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Application

Research Applications
Clinical Applications

By Technique

Nanopore Sequencing
Synthetic Long Read Sequencing
Single-Molecule Real-Time (SMRT) Sequencing

By Product

Instruments
- Type
- System
- Software
Consumables
Services

By End User

Academic and Government Research Institutes
Pharmaceutical and Biotech Companies
Hospitals and Clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Cantata Bio
Illumina, Inc.
Danaher Corporation
Element Biosciences
FG Technologies
MicrobesNG
Oxford Nanopore Technologies plc.
CD Genomics
BGI Genomics
St Vincents Hospital Melbourne
Agilent Technologies, Inc.
TAKARA HOLDINGS INC.
BaseClear B.V.
GrandOmics
Novogene co., ltd.
PacBio
Thermo Fisher Scientific Inc.

Product Code: A14421

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in demand for precision medicine
  - 3.4.1.2. Rise in number of partnership and collaboration
  - 3.4.1.3. The growing initiatives taken by the key players for drug discovery
- 3.4.2. Restraints
  - 3.4.2.1. High Initial Investment and Cost
- 3.4.3. Opportunities
  - 3.4.3.1. Rise in technological advancements

CHAPTER 4: LONG READ SEQUENCING MARKET, BY APPLICATION

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Research Applications
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Clinical Applications
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: LONG READ SEQUENCING MARKET, BY TECHNIQUE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Single-Molecule Real-Time (SMRT) Sequencing
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Nanopore Sequencing
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Synthetic Long Read Sequencing
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: LONG READ SEQUENCING MARKET, BY PRODUCT

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Instruments
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.2.4. Instruments Long Read Sequencing Market by Type
6.3. Consumables
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Services
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: LONG READ SEQUENCING MARKET, BY END USER

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Academic and Government Research Institutes
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Pharmaceutical and Biotech Companies
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
7.4. Hospitals and Clinics
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country
7.5. Others
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by region
- 7.5.3. Market share analysis by country

CHAPTER 8: LONG READ SEQUENCING MARKET, BY REGION

8.1. Overview
- 8.1.1. Market size and forecast By Region
8.2. North America
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by Application
- 8.2.3. Market size and forecast, by Technique
- 8.2.4. Market size and forecast, by Product
- 8.2.5. Market size and forecast, by End User
- 8.2.6. Market size and forecast, by country
  - 8.2.6.1. U.S.
  - 8.2.6.1.1. Market size and forecast, by Application
  - 8.2.6.1.2. Market size and forecast, by Technique
  - 8.2.6.1.3. Market size and forecast, by Product
  - 8.2.6.1.4. Market size and forecast, by End User
  - 8.2.6.2. Canada
  - 8.2.6.2.1. Market size and forecast, by Application
  - 8.2.6.2.2. Market size and forecast, by Technique
  - 8.2.6.2.3. Market size and forecast, by Product
  - 8.2.6.2.4. Market size and forecast, by End User
  - 8.2.6.3. Mexico
  - 8.2.6.3.1. Market size and forecast, by Application
  - 8.2.6.3.2. Market size and forecast, by Technique
  - 8.2.6.3.3. Market size and forecast, by Product
  - 8.2.6.3.4. Market size and forecast, by End User
8.3. Europe
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by Application
- 8.3.3. Market size and forecast, by Technique
- 8.3.4. Market size and forecast, by Product
- 8.3.5. Market size and forecast, by End User
- 8.3.6. Market size and forecast, by country
  - 8.3.6.1. Germany
  - 8.3.6.1.1. Market size and forecast, by Application
  - 8.3.6.1.2. Market size and forecast, by Technique
  - 8.3.6.1.3. Market size and forecast, by Product
  - 8.3.6.1.4. Market size and forecast, by End User
  - 8.3.6.2. France
  - 8.3.6.2.1. Market size and forecast, by Application
  - 8.3.6.2.2. Market size and forecast, by Technique
  - 8.3.6.2.3. Market size and forecast, by Product
  - 8.3.6.2.4. Market size and forecast, by End User
  - 8.3.6.3. UK
  - 8.3.6.3.1. Market size and forecast, by Application
  - 8.3.6.3.2. Market size and forecast, by Technique
  - 8.3.6.3.3. Market size and forecast, by Product
  - 8.3.6.3.4. Market size and forecast, by End User
  - 8.3.6.4. Italy
  - 8.3.6.4.1. Market size and forecast, by Application
  - 8.3.6.4.2. Market size and forecast, by Technique
  - 8.3.6.4.3. Market size and forecast, by Product
  - 8.3.6.4.4. Market size and forecast, by End User
  - 8.3.6.5. Spain
  - 8.3.6.5.1. Market size and forecast, by Application
  - 8.3.6.5.2. Market size and forecast, by Technique
  - 8.3.6.5.3. Market size and forecast, by Product
  - 8.3.6.5.4. Market size and forecast, by End User
  - 8.3.6.6. Rest of Europe
  - 8.3.6.6.1. Market size and forecast, by Application
  - 8.3.6.6.2. Market size and forecast, by Technique
  - 8.3.6.6.3. Market size and forecast, by Product
  - 8.3.6.6.4. Market size and forecast, by End User
8.4. Asia-Pacific
- 8.4.1. Key market trends, growth factors and opportunities
- 8.4.2. Market size and forecast, by Application
- 8.4.3. Market size and forecast, by Technique
- 8.4.4. Market size and forecast, by Product
- 8.4.5. Market size and forecast, by End User
- 8.4.6. Market size and forecast, by country
  - 8.4.6.1. Japan
  - 8.4.6.1.1. Market size and forecast, by Application
  - 8.4.6.1.2. Market size and forecast, by Technique
  - 8.4.6.1.3. Market size and forecast, by Product
  - 8.4.6.1.4. Market size and forecast, by End User
  - 8.4.6.2. China
  - 8.4.6.2.1. Market size and forecast, by Application
  - 8.4.6.2.2. Market size and forecast, by Technique
  - 8.4.6.2.3. Market size and forecast, by Product
  - 8.4.6.2.4. Market size and forecast, by End User
  - 8.4.6.3. India
  - 8.4.6.3.1. Market size and forecast, by Application
  - 8.4.6.3.2. Market size and forecast, by Technique
  - 8.4.6.3.3. Market size and forecast, by Product
  - 8.4.6.3.4. Market size and forecast, by End User
  - 8.4.6.4. Australia
  - 8.4.6.4.1. Market size and forecast, by Application
  - 8.4.6.4.2. Market size and forecast, by Technique
  - 8.4.6.4.3. Market size and forecast, by Product
  - 8.4.6.4.4. Market size and forecast, by End User
  - 8.4.6.5. South Korea
  - 8.4.6.5.1. Market size and forecast, by Application
  - 8.4.6.5.2. Market size and forecast, by Technique
  - 8.4.6.5.3. Market size and forecast, by Product
  - 8.4.6.5.4. Market size and forecast, by End User
  - 8.4.6.6. Rest of Asia-Pacific
  - 8.4.6.6.1. Market size and forecast, by Application
  - 8.4.6.6.2. Market size and forecast, by Technique
  - 8.4.6.6.3. Market size and forecast, by Product
  - 8.4.6.6.4. Market size and forecast, by End User
8.5. LAMEA
- 8.5.1. Key market trends, growth factors and opportunities
- 8.5.2. Market size and forecast, by Application
- 8.5.3. Market size and forecast, by Technique
- 8.5.4. Market size and forecast, by Product
- 8.5.5. Market size and forecast, by End User
- 8.5.6. Market size and forecast, by country
  - 8.5.6.1. Brazil
  - 8.5.6.1.1. Market size and forecast, by Application
  - 8.5.6.1.2. Market size and forecast, by Technique
  - 8.5.6.1.3. Market size and forecast, by Product
  - 8.5.6.1.4. Market size and forecast, by End User
  - 8.5.6.2. Saudi Arabia
  - 8.5.6.2.1. Market size and forecast, by Application
  - 8.5.6.2.2. Market size and forecast, by Technique
  - 8.5.6.2.3. Market size and forecast, by Product
  - 8.5.6.2.4. Market size and forecast, by End User
  - 8.5.6.3. South Africa
  - 8.5.6.3.1. Market size and forecast, by Application
  - 8.5.6.3.2. Market size and forecast, by Technique
  - 8.5.6.3.3. Market size and forecast, by Product
  - 8.5.6.3.4. Market size and forecast, by End User
  - 8.5.6.4. Rest of LAMEA
  - 8.5.6.4.1. Market size and forecast, by Application
  - 8.5.6.4.2. Market size and forecast, by Technique
  - 8.5.6.4.3. Market size and forecast, by Product
  - 8.5.6.4.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

10.1. Agilent Technologies, Inc.
- 10.1.1. Company overview
- 10.1.2. Key executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Business performance
10.2. BaseClear B.V.
- 10.2.1. Company overview
- 10.2.2. Key executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
10.3. Cantata Bio
- 10.3.1. Company overview
- 10.3.2. Key executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Key strategic moves and developments
10.4. Element Biosciences
- 10.4.1. Company overview
- 10.4.2. Key executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.6. Key strategic moves and developments
10.5. FG Technologies
- 10.5.1. Company overview
- 10.5.2. Key executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
10.6. GrandOmics
- 10.6.1. Company overview
- 10.6.2. Key executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Key strategic moves and developments
10.7. Illumina, Inc.
- 10.7.1. Company overview
- 10.7.2. Key executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
- 10.7.6. Business performance
- 10.7.7. Key strategic moves and developments
10.8. MicrobesNG
- 10.8.1. Company overview
- 10.8.2. Key executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
10.9. Novogene co., ltd.
- 10.9.1. Company overview
- 10.9.2. Key executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.9.6. Key strategic moves and developments
10.10. Oxford Nanopore Technologies plc.
- 10.10.1. Company overview
- 10.10.2. Key executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- 10.10.6. Key strategic moves and developments
10.11. PacBio
- 10.11.1. Company overview
- 10.11.2. Key executives
- 10.11.3. Company snapshot
- 10.11.4. Operating business segments
- 10.11.5. Product portfolio
- 10.11.6. Business performance
- 10.11.7. Key strategic moves and developments
10.12. St Vincents Hospital Melbourne
- 10.12.1. Company overview
- 10.12.2. Key executives
- 10.12.3. Company snapshot
- 10.12.4. Operating business segments
- 10.12.5. Product portfolio
10.13. TAKARA HOLDINGS INC.
- 10.13.1. Company overview
- 10.13.2. Key executives
- 10.13.3. Company snapshot
- 10.13.4. Operating business segments
- 10.13.5. Product portfolio
- 10.13.6. Business performance
10.14. Thermo Fisher Scientific Inc.
- 10.14.1. Company overview
- 10.14.2. Key executives
- 10.14.3. Company snapshot
- 10.14.4. Operating business segments
- 10.14.5. Product portfolio
- 10.14.6. Business performance
10.15. Danaher Corporation
- 10.15.1. Company overview
- 10.15.2. Key executives
- 10.15.3. Company snapshot
- 10.15.4. Operating business segments
- 10.15.5. Product portfolio
- 10.15.6. Business performance
10.16. BGI Genomics
- 10.16.1. Company overview
- 10.16.2. Key executives
- 10.16.3. Company snapshot
- 10.16.4. Operating business segments
- 10.16.5. Product portfolio
10.17. CD Genomics
- 10.17.1. Company overview
- 10.17.2. Key executives
- 10.17.3. Company snapshot
- 10.17.4. Operating business segments
- 10.17.5. Product portfolio